Healthcare firms help European unicorns set record pace in 2021 –

August 11, 2021 ( Newswire) Economic uncertainty in Europe has failed to stop record growth by unicorn companies in 2021, with healthcare businesses amongst the biggest winners.

This buoyant trend defies continental nervousness due to intermittent lockdowns, rising unemployment, unpredictable economic growth, COVID-19 variants, and a sluggish vaccination supply throughout 2020 and 2021.

Twenty-three European and Israeli unicorn companies – private firms valued at a billion or more – have already completed deals this year, according to investment monitoring platform Pitchbook, closing in fast on 2020’s total of 38.

The approximate market value of unicorns in Europe also grew to €122.5 billion in Q1 2021, and Pitchbook now expects a new record for unicorn deals this year.

Healthcare technology investment soared 47% in 2020 to a new sector high of $51bn. Venture capital fundraising was also robust, with $17bn made available for healthcare investment, with deal sizes rising to record levels during 2021 so far.

This surge suggests a response to weaknesses exposed in healthcare systems across Europe last year. Healthcare technology specialists Vector Innovation Fund expects investors to focus further on healthcare in forthcoming years to guard against future global healthcare disasters and pandemic preparedness for infectious diseases.

World Nano Foundation, a not-for-profit organisation that supports commercialising nanoscale technology such as nanomedicines, and its co-founder Paul Sheedy welcomed the increased financial backing for healthcare innovation:

“COVID-19 pushed the over-centralised global healthcare systems to their limit in 2020, so it’s very promising to see investors supporting and driving the healthtech sector forward that supports early intervention and prevention delivered at the point of care, but this must continue, as the next decade will be pivotal in shaping the future of healthcare.

“We are on the cusp of some ground-breaking innovations. Healthtech companies are working towards improving treatment for cancer, Alzheimer’s and other degenerative diseases, enhancing pandemic protection through improved vaccine technology and testing, and providing digitisation that can enable us to create a more decentralised and sustainable global healthcare system. However, to see this future, we must maintain investment momentum.”

Paul Stannard, chairman and general partner at Vector Innovation Fund (VIF), which specialises in investment within healthcare technology and pandemic protection, supports this message, adding:

“The pandemic has highlighted that early intervention is key to meeting the biggest health challenges and moving to a more decentralised model focussed upon sustainable health and improving life longevity. This is being achieved through new healthcare technologies, and this investment trend is set to continue because of the enormous upsides and impact it is delivering.

“It’s so positive to see record investment and deal sizes within healthcare and healthtech, showing that investment into this sector is more than just a positive impact investment, but an investment that appeals to the profit-driven investor too, offering sound investments and strong returns.”

For further information or interviews with The World Nano Foundation or Vector Innovation Fund please contact: or +44 7973159065

The World Nano Foundation is a not-for-profit membership organisation with 75,000 subscribers and users in 40 countries working on international commercialisation of nanoscale technologies in 16 industry sectors and collaborates with a wide variety of partners, maximising support and funding and bringing advanced technology to the world and commerce. This is supported by many industries and academic groups developing and creating a legacy for enabling technology innovation.

Vector Innovation Fund (VIF) is a Reserved Alternative Investment Fund (RAIF) specialising in support for technology companies able to transform and protect global markets, notably in global healthcare, enabling technology, sustainability, and longevity aligned to the UN’s SDG principles.

VIF focuses on healthcare technology and other enabling technologies that support sustainable outcomes. The fund is domiciled in the world-renowned Luxembourg jurisdiction, and open only to international accredited and professional investors, such as family offices, UHNW, private placement investors, pension funds, international banks, ESG investors and sovereign wealth funds. The General Partners have an excellent track record in industry, healthcare, technology and investment, with 21 exits and a total value creation of $2.4billion, including two successful IPOs.

More Info: Newswire

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits - A Leading Global Investor Website for Biotech Industry Stocks

Buy a biotech guest post on

Spread the love

Leave a Reply

Your email address will not be published.